TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06431776: An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Sponsor: Savara Inc. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,331,320

Rescue Site Savings

+$2,204,550

Unlock Full NCT06431776 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06431776 Rescue Dossier →